All In Biotech

Drug Trial Radar · NCT01506141

An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment

An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment

Last checked: Nov 20, 2026Latest source record: Aug 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

15

Actual

Start

Aug 1, 2010

Primary completion

Apr 30, 2024

Study completion Apr 30, 2024

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jan 9, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 3 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This extension study of HGT-HIT-045 is designed to collect long-term safety data in pediatric participants with Hunter syndrome and cognitive impairment who are receiving intrathecal (IT) idursulfase-IT and intravenous (IV) Elaprase enzyme replacement therapy.

Conditions

  • Hunter Syndrome

Interventions

  • Idursulfase-ITDrug

    Idursulfase-IT once monthly via IDDD.

  • ElapraseDrug

    Weekly IV infusions of commercially available Elaprase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From start of study drug administration up to follow-up (up to 165 months)
  2. Number of Participants With Clinically Significant Changes or Apparent Difference Across Treatment Groups in Laboratory ParametersTime frame: From start of study drug administration up to follow-up (up to 165 months)
  3. Number of Participants With Clinically Significant Changes or Apparent Difference Across Treatment Groups in 12-lead Electrocardiogram (ECG) FindingsTime frame: From start of study drug administration up to follow-up (up to 165 months)
  4. CSF Chemistries: Change From Baseline in CSF Total Cell CountTime frame: Baseline, Month 163
  5. CSF Chemistries: Change From Baseline in CSF GlucoseTime frame: Baseline, Month 163
  6. CSF Chemistries: Change From Baseline in CSF ProteinTime frame: Baseline, Month 163
  7. Number of Participants With Anti-idursulfase Antibodies in CSFTime frame: From start of study drug administration up to follow-up (up to 165 months)
  8. Number of Participants With Anti-idursulfase Antibodies in SerumTime frame: From start of study drug administration up to follow-up (up to 165 months)

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • Ann & Robert H Lurie Childrens Hospital of Chicago

    Chicago, Illinois

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Legacy Emanuel Hospital

    Portland, Oregon

  • Children's Hospital of Pittsburgh of UPMC

    Pittsburgh, Pennsylvania

  • Vanderbilt Children's Hospital

    Nashville, Tennessee

  • University of Utah Hospital

    Salt Lake City, Utah

  • Seattle Children's Hospital

    Seattle, Washington

  • British Columbia Children's Hospital

    Vancouver, British Columbia, Canada

  • Birmingham Children's Hospital

    Birmingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.